Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other solid neoplasm 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

zanubrutinib 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1Voriconazole 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × B-cell Malignancies × Clear all
NCT01905813 2026-05-11

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Incyte Corporation

Phase 1 Completed
121 enrolled
Lymphoid

B-cell Malignancies

NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

NCT06958679 2025-05-14

Evaluation of SYS6005 in Patients With Advanced Malignant Tumor

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 1 Recruiting
132 enrolled
LymphoidOther solid neoplasm

B-cell Malignancies

NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡